For sleep-deprived nursing moms, artificial intelligence may feel like a lifeline. In fact, a new national survey from Orlando Health reveals if women ages 18 to 44 had an urgent breastfeeding question or concern half (51%) of them would first turn to an AI chatbot, social media or a search engine.

A mysterious black lesion that forms on cats’ eyes has puzzled veterinarians for years. Now, researchers have identified iron and bromine in the affected corneal tissue, offering new clues to what may drive the condition. The findings could help explain why the tissue becomes dark and damaged, while potentially opening new directions for future diagnosis and treatment.

USC researchers found that exposure to common outdoor air pollutants may be linked to changes in brain regions especially vulnerable to Alzheimer’s disease. The study analyzed brain scans and residential pollution estimates from 1,484 adults without dementia or a history of stroke.

Among older women, higher exposure to fine particulate matter (PM2.5) and nitrogen dioxide (NO2) was associated with a thinner cortex in memory-related brain regions commonly affected by Alzheimer’s disease. A separate group of younger men showed a different pattern, with greater pollution exposure associated with a thicker cortex in the same regions. That association weakened with age and reversed around age 65.

The findings suggest the brain’s response to air pollution may change across the aging process. Because the groups differed in age and sex, and participants were assessed at one point in time, the study cannot determine whether pollution caused the observed differences or explain why the patterns varied. Longer-term studies are needed to examine whether these brain changes are linked to inflammation, Alzheimer’s-related biomarkers and future dementia risk.

ARDD 2026 has announced that Adiv Johnson, Ph.D., Chief Scientific Officer at Tally Health, will speak at the 13th Aging Research & Drug Discovery (ARDD) Meeting, taking place October 1–3, 2026, at the David Rubenstein Treehouse at Harvard University. As the world's leading conference dedicated to longevity biotechnology, ARDD 2026 will convene top researchers, pharmaceutical executives, entrepreneurs, and investors to accelerate the translation of aging science into next-generation medicines.

Organized by Insilico Medicine and supported by industry leaders including Eli Lilly and the McKinsey Health Institute, the meeting reflects the growing momentum behind longevity as a major frontier in biomedical innovation. With speakers representing ten of the world's leading pharmaceutical companies, ARDD 2026 aims to foster the collaborations needed to transform discoveries in aging biology into therapies that extend healthy lifespan and improve patient outcomes.

ARDD 2026 has announced that Christophe Weber, former CEO of Takeda, will speak at the 13th Aging Research & Drug Discovery (ARDD) Meeting, taking place October 1–3, 2026, at the David Rubenstein Treehouse at Harvard University. As the world's leading conference dedicated to longevity biotechnology, ARDD 2026 will convene top researchers, pharmaceutical executives, entrepreneurs, and investors to accelerate the translation of aging science into next-generation medicines.

Organized by Insilico Medicine and supported by industry leaders including Eli Lilly and the McKinsey Health Institute, the meeting reflects the growing momentum behind longevity as a major frontier in biomedical innovation. With speakers representing ten of the world's leading pharmaceutical companies, ARDD 2026 aims to foster the collaborations needed to transform discoveries in aging biology into therapies that extend healthy lifespan and improve patient outcomes.

ARDD 2026 has announced that Kan Chen, Ph.D., Co-Head of Healthcare and Partner at Qiming Venture Partners, will speak at the 13th Aging Research & Drug Discovery (ARDD) Meeting, taking place October 1–3, 2026, at the David Rubenstein Treehouse at Harvard University. As the world's leading conference dedicated to longevity biotechnology, ARDD 2026 will convene top researchers, pharmaceutical executives, entrepreneurs, and investors to accelerate the translation of aging science into next-generation medicines.

Organized by Insilico Medicine and supported by industry leaders including Eli Lilly and the McKinsey Health Institute, the meeting reflects the growing momentum behind longevity as a major frontier in biomedical innovation. With speakers representing ten of the world's leading pharmaceutical companies, ARDD 2026 aims to foster the collaborations needed to transform discoveries in aging biology into therapies that extend healthy lifespan and improve patient outcomes.